The C677T polymorphism of the methylenetetrahydrofolate reductase gene is associated with the level of decrease on diastolic blood pressure in essential hypertension patients treated by angiotensin-converting enzyme inhibitor

Thrombosis Research
S JiangXiping Xu

Abstract

Elevated plasma homocysteine has been implicated as a risk factor for hypertension. C677T polymorphism in methylenetetrahydrofolate reductase gene (MTHFR) is a major determinant of hyperhomocysteinemia, which results in endothelial dysfunction. Angiotensin-converting enzyme (ACE) inhibitors appear to remedy the endothelial dysfunction and restore endothelium-dependent vasodilatation. The co-existence of genetic polymorphisms in drug metabolizing enzymes, targets, receptors, and transporters may influence the drug efficacy. The purpose of this study was to investigate whether short-term blood pressure control by benazepril, an ACE inhibitor, was modulated by C677T MTHFR gene polymorphism. A total of 444 hypertensive patients, aged 27 to 65 years, without any anti hypertensive therapy within 2 weeks were included. All of them were treated orally with benazepril at a single daily fixed dosage of 10 mg for 15 consecutive days. Blood pressures were measured at baseline and on the 16th day of treatment. Among them, the frequency of MTHFR C677T genotype CC, CT and TT was 24.3%, 51.8%, and 23.9%, respectively. In a recessive model (CC+CT versus TT genotype), both baseline diastolic blood pressure (DBP) and diastolic blood pressure resp...Continue Reading

References

Nov 15, 1995·JAMA : the Journal of the American Medical Association·O NygårdG Kvåle
Oct 4, 1995·JAMA : the Journal of the American Medical Association·C J BousheyA G Motulsky
Jun 13, 2000·Circulation Research·E S StroesT J Rabelink
Apr 17, 2001·BMJ : British Medical Journal·G BeeversE O'Brien
Dec 14, 2002·American Journal of Epidemiology·Unhee Lim, Patricia A Cassano
Feb 7, 2003·The New England Journal of Medicine·Richard Weinshilboum
Jun 12, 2003·Clinical and Experimental Hypertension : CHE·Francisco Rodríguez-EsparragónCarlos M Ferrario

❮ Previous
Next ❯

Citations

Oct 18, 2013·The Proceedings of the Nutrition Society·R ReillyM Ward
May 19, 2012·International Journal of Biological Sciences·Rui-Xing YinMeng Li
Oct 31, 2012·International Journal of Molecular Sciences·Rui-Xing YinMeng Li
Sep 6, 2013·Genome Research·Michael J FlisterCarol Moreno
Jul 30, 2010·Journal of Zhejiang University. Science. B·Fang-fang FanJian-ping Li
Aug 29, 2014·American Journal of Hypertension·Eliyahu M Heifetz, Ruth Z Birk
Oct 10, 2018·Annual Review of Pharmacology and Toxicology·Tanima DeMinoli A Perera
Oct 25, 2007·American Journal of Human Biology : the Official Journal of the Human Biology Council·K N SaraswathyA K Kalla
Mar 15, 2006·Current Opinion in Lipidology·Sophie Visvikis-Siest, Jean-Brice Marteau
Nov 1, 2007·Personalized Medicine·Jean-Brice MarteauSophie Visvikis-Siest

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.